EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Dec 2 () - Wegovy maker Novo Nordisk is planning ​to test its experimental obesity drug, ‌CagriSema, in overweight children ...

Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...

Semaglutide and tirzepatide, the latter marketed by US-based Eli Lilly in India as Mounjaro, belong to the GLP-1 class of ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...